関連する実験動画
Updated: Sep 10, 2025

10:08
Measuring Ascending Aortic Stiffness In Vivo in Mice Using Ultrasound
Published on: December 2, 2014
16.1K
大動脈 の 硬さ と アルツハイマー 病:メディンの 関係
Filippos Triposkiadis1,2, Andrew Xanthopoulos1,2, Harisios Boudoulas3
1European University Cyprus, 1516 Nicosia, Cyprus.
Biomolecules
|August 28, 2025
まとめ
老化に関連した大動脈の硬化は,メディンというタンパク質の断片を通してアルツハイマー病 (AD) に寄与する可能性があります. メディンはアミロイドの蓄積と炎症を促進し,潜在的にADの新たな治療標的を提供している.
科学分野:
- ゲロントロジー
- 神経科学
- 心血管科学
背景:
- 老化により大動脈の硬化 (AoSt) が起こり,弾力性が低下し,アルツハイマー病 (AD) を含む認知機能低下のリスクが増加します.
- MFG-E8から派生したメディンは,AoStとADの関連性に関与している.
- メディンは大動脈中部アミロイド (AMA) を形成し,高齢者に多く見られ,血管の炎症と化を引き起こします.
研究 の 目的:
- 年齢による大動脈硬化と アルツハイマー病の間の 重要なリンクとして働くという仮説を 探求するためです
- 脳血管機能障害と神経炎症を 促進するメディンの役割を調べるため
主な方法:
- 血管と脳の病理学におけるメディンの役割に関する新たな証拠のレビュー.
- メディンのアミロイドベータ (Aβ) との相互作用とそのアミロイド病理学的貢献の分析.
- 内皮機能,酸化ストレス,および膠質細胞活性化に対するメディンの影響の検討.
主要な成果:
- 血管の炎症,結石化,動脈の弾性低下に寄与する.
- 脳の血管機能障害と神経炎症を引き起こす.
- メディンは炎症を助長し 認知機能の低下を助長します
結論:
- メディンは大動脈の硬化と アルツハイマー病を 繋ぐ架け橋のような役割を果たすかもしれません
- 血管と神経炎症におけるメディンの役割は,ADの新たな治療目標の可能性を示唆しています.
- ADにおけるメディンの役割のさらなる実験的および臨床的検証が必要である.
さらに関連する動画
関連する概念動画
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
38
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
38
Atherosclerosis I: Introduction
76
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
76
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
52
Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
52
Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33

